Trends in methicillin-resistant Staphylococcus aureus detection-rates and antibiotic resistance profiles in a cancer hospital from 2015 to 2024 Authors: Hui Wang, Qin Huang, Qingqing Tian, Weiwei Yang, Anran Liu, Jiayang Tang, Hailin Zhang, Chunlin Wu Published: 2026 ABSTRACT BackgroundMethicillin-resistant Staphylococcus aureus (MRSA) is an important antimicrobial-resistant organism in healthcare settings, and long-term surveillance is important for infection prevention and antimicrobial stewardship. Long-term epidemiological data on MRSA remain limited, particularly in cancer specialty hospitals. This study aimed to investigate the distribution and antimicrobial resistance trends of MRSA in a cancer hospital over a ten-year period (2015–2024).MethodsWe analyzed data from clinical isolates obtained at Sichuan Cancer Hospital between 2015 and 2024. Patient demographics, departmental sources, specimen information, hospital-acquired infection classification, and antimicrobial susceptibility testing results were collected. The epidemiological distribution and temporal trends in MRSA resistance were assessed over the study period.ResultsAmong 13,829 hospitalization records with at least one positive culture, 1,550 Staphylococcus aureus isolates were identified. Of these, 433 were identified as MRSA (detection rate 27.94%). The MRSA detection rate initially increased, peaked at 35.48% in 2018, and then gradually declined; however, the interannual variations were not statistically significant. MRSA was detected across 23 departments. The highest number of MRSA isolates was detected in Surgery, particularly Head and Neck Surgery (54 isolates, 12.47%), followed by Radiotherapy, Internal Medicine, and other departments. Among MRSA detections classified as hospital-acquired infections, the largest number occurred in Head and Neck Surgery (31 cases, 20.95%). The Head and Neck Radiotherapy Ward and Thoracic Surgery Ward also had relatively high numbers of MRSA-associated hospital-acquired infections. The main infection sites among MRSA-associated hospital-acquired infections were the lower respiratory tract (60 cases, 40.54%) and surgical sites (32 cases, 21.62%). Regarding antimicrobial resistance, the resistance rates of MRSA to most tested antimicrobial agents did not show a clear increasing or decreasing trend. MRSA remained fully susceptible to daptomycin, linezolid, tigecycline, and vancomycin (all with 0% resistance). Exploratory analyses showed interannual differences in resistance rates for erythromycin, chloramphenicol, and moxifloxacin, but these findings should be interpreted cautiously.ConclusionThis ten-year surveillance study in a cancer specialty hospital showed an average MRSA detection rate of 27.94%, with departmental heterogeneity in MRSA detection and in MRSA-associated hospital-acquired infections. Head and Neck Surgery accounted for the largest number of MRSA-associated hospital-acquired infections, whereas the Neurosurgery Ward had the highest MRSA detection rate. Antimicrobial susceptibility testing showed that resistance rates of MRSA to most agents remained stable. These findings may inform local empirical therapy, antimicrobial stewardship, and department-specific infection prevention strategies, but they should not be interpreted as direct evidence for individualized treatment decisions.Clinical trial numberNot applicable. In cancer specialty hospitals, long-term epidemiological data on MRSA are limited.As one of the most frequently detected multidrug-resistant bacteria in hospital settings, MRSA significantly impacts hospital-associated infections.This study identifies departments with high MRSA detection frequencies and rates, as well as the predominant infection types, providing descriptive data to inform department-level infection prevention and control strategies.The findings suggest that key antimicrobial susceptibilities have remained relatively stable over the study period, supporting the continued availability of treatment options for severe infections.Exploratory analyses identified variations in resistance rates to certain antimicrobials, such as erythromycin, which may warrant further investigation as potential signals of shifting resistance patterns. In cancer specialty hospitals, long-term epidemiological data on MRSA are limited. In cancer specialty hospitals, long-term epidemiological data on MRSA are limited. As one of the most frequently detected multidrug-resistant bacteria in hospital settings, MRSA significantly impacts hospital-associated infections. As one of the most frequently detected multidrug-resistant bacteria in hospital settings, MRSA significantly impacts hospital-associated infections. This study identifies departments with high MRSA detection frequencies and rates, as well as the predominant infection types, providing descriptive data to inform department-level infection prevention and control strategies. This study identifies departments with high MRSA detection frequencies and rates, as well as the predominant infection types, providing descriptive data to inform department-level infection prevention and control strategies. The findings suggest that key antimicrobial susceptibilities have remained relatively stable over the study period, supporting the continued availability of treatment options for severe infections. The findings suggest that key antimicrobial susceptibilities have remained relatively stable over the study period, supporting the continued availability of treatment options for severe infections. Exploratory analyses identified variations in resistance rates to certain antimicrobials, such as erythromycin, which may warrant further investigation as potential signals of shifting resistance patterns. Exploratory analyses identified variations in resistance rates to certain antimicrobials, such as erythromycin, which may warrant further investigation as potential signals of shifting resistance patterns. Introduction Methicillin-resistant Staphylococcus aureus (MRSA) is a multidrug-resistant pathogen of major clinical and public health concern in both healthcare and community settings worldwide [1]. The rise and dissemination of MRSA present substantial challenges to public health, particularly in hospitals, where MRSA infections are associated with prolonged hospitalization, increased treatment costs, and elevated mortality rates, establishing it as a critical target for infection control efforts [2]. The global prevalence of MRSA remains high, although detection rates vary considerably across regions and healthcare facilities [3–6]. Moreover, the antimicrobial resistance profile of MRSA continues to evolve, demonstrating increasing resistance to multiple antibiotic classes [7–9]. Long-term epidemiological data on MRSA remain limited, with this gap being especially pronounced in cancer specialty hospitals. Continuous monitoring of MRSA distribution and resistance trends within hospitals is therefore essential for guiding infection control policies, promoting rational antibiotic use, and developing effective prevention strategies. This study analyzes clinical isolates from a single hospital between 2015 and 2024 to characterize the epidemiology and antimicrobial resistance patterns of MRSA, thereby providing evidence to support hospital infection control and antimicrobial stewardship. Materials and methods Data collection Data were extracted from the clinical specimen test results of Sichuan Cancer Hospital between 2015 and 2024. General patient information corresponding to the specimens was also collected. The inclusion criteria were as follows: (1) specimens with positive culture results; (2) for patients with repeated detection of the same microorganism during a single hospitalization, only the first detection result was included. Exclusion criteria included incomplete data. Methicillin-resistantStaphylococcus aureus (MRSA) was defined as Staphylococcus aureus resistant to any one of the following antimicrobial agents: oxacillin, cefoxitin, or methicillin. Otherwise, it was classified as Methicillin-Sensitive Staphylococcus aureus (MSSA). General patient information of patients with positive culture results from 2015 to 2024 was retrieved through the “Hospital Infection Real-Time Monitoring System.” The collected variables included sex, age, hospitalization duration, department, microbiological results, specimen source, and whether the case met the surveillance criteria for healthcare-associated infection. For the classification of hospital-acquired infection, the operational rules were refined with reference to the Hospital Infection Case Identification Standard: General Principles (WS/T 857–2025), issued by the National Health Commission of China. This standard was used for surveillance classification of healthcare-associated infections and not as a substitute for clinical diagnosis or treatment decision-making. A case was classified as a hospital-acquired infection only when the MRSA-positive culture was supported by compatible clinical evidence of infection and the infection was considered to have been acquired during hospitalization. In accordance with the general principles, classification was based on a comprehensive review of clinical manifestations, epidemiological information, imaging findings, laboratory results, microbiological evidence, physician diagnosis, and other medical-record information. Infections with a defined incubation period were considered hospital-acquired when the interval from admission to onset exceeded the average incubation period; infections without a defined incubation period were considered hospital-acquired when onset occurred more than 48 h after admission. Infections directly related to a previous hospitalization, and new infections occurring at a different anatomical site from a pre-existing infection, were also classified as hospital-acquired after excluding metastatic foci of sepsis and complications or natural extension of the original infection. The following situations were not classified as hospital-acquired MRSA infection: infection already present or in the incubation period at admission; natural extension of an infection present at admission unless the pathogen or clinical manifestations strongly suggested a new infection; non-infectious inflammatory conditions caused by trauma or non-biological factors; positive MRSA culture judged to represent contamination or colonization without compatible symptoms, signs, imaging changes, or laboratory evidence of infection; and recurrent infection of the same type within a 14-day repeat-infection timeframe. Clinical physicians and infection-control professionals jointly reviewed the surveillance records when classification was uncertain. Methods MRSA identification and antimicrobial susceptibility testing The standard for antimicrobial susceptibility testing is the Clinical and Laboratory Standards Institute Guidelines (CLSI) M100-Ed34 [10]. MRSA identification and antimicrobial susceptibility testing were performed using the VITEK-2 automated microbiology system (bioMérieux, France). The tested antibiotics included: benzylpenicillin, ampicillin, oxacillin, cefoxitin, gentamicin, erythromycin, clindamycin, levofloxacin, moxifloxacin, vancomycin, daptomycin, linezolid, tigecycline, trimethoprim-sulfamethoxazole, rifampicin, and quinupristin/dalfopristin. For daptomycin and vancomycin, which had limited detection conditions on the VITEK-2 system, as well as for tetracycline, ceftriaxone, and chloramphenicol, which were not covered by the system, the Kirby-Bauer disk diffusion method was used as a supplementary test. MRSA detection rates and trends observation Detection rate of Staphylococcus aureus= (Number of Staphylococcus aureus isolates detected during a specified period / Total number of positive culture results from hospitalized patients during the same period) × 100%. Detection rate of MRSA= (Number of MRSA isolates detected during a specified period / Total number of Staphylococcus aureus isolates detected during the same period) × 100%. Based on the antimicrobial susceptibility testing results, the resistance rates of MRSA to various antibiotics were calculated. Using year as the grouping variable, the detection rates and resistance rates of MRSA in different years were statistically analyzed. Meanwhile, using clinical department as the grouping variable, the detection status of MRSA in different departments was statistically analyzed, thereby evaluating the trends in clinical distribution and resistance characteristics of MRSA. Relevant definitions In this study, the following operational definitions were used: MRSA detection/isolation was defined as a positive laboratory result in which methicillin-resistant Staphylococcus aureus was isolated and identified from a clinical specimen. This category included both colonization and infection and was not interpreted by itself as evidence of clinical infection. MRSA colonization was defined as the presence of MRSA at a body site, such as the anterior nares, skin, respiratory tract, wound surface, perineum, or tracheostomy site, without clinical manifestations or objective evidence of infection at that site. MRSA infection was defined as MRSA detection from a relevant clinical specimen together with compatible clinical manifestations and objective evidence supporting infection at the corresponding anatomical site. For lower respiratory tract infection, classification required compatible respiratory symptoms or clinical deterioration together with supporting evidence such as radiological findings, purulent respiratory secretions, inflammatory markers, physician diagnosis, and/or targeted antimicrobial treatment. For surgical site infection, classification was based on postoperative wound or organ/space findings such as purulent drainage, local inflammatory signs, wound dehiscence or abscess, positive culture from an appropriate specimen, physician diagnosis, and/or anti-infective treatment. For skin and soft tissue infection, classification required local inflammatory signs, purulent exudate or abscess, compatible specimen culture, physician diagnosis, and/or targeted treatment. Cases lacking these supporting features were classified as MRSA detection or colonization rather than infection. MRSA-associated hospital-acquired infection was defined as an MRSA infection that met the above infection criteria and the surveillance criteria for hospital acquisition. The 48-hour threshold was therefore applied as a temporal criterion, but it was not used as the sole basis for distinguishing infection from colonization, contamination, or infection already present before admission. Statistical analysis Data were organized using Excel. Statistical analysis was performed using SPSS 21.0 software. Continuous variables were expressed as mean +/- standard deviation and compared using the t-test. Rates were compared using the chi-square test. A P-value < 0.05 was considered statistically significant. Analyses of antimicrobial resistance trends across multiple agents were exploratory. No formal correction for multiple comparisons was applied, and statistically significant findings from these analyses were interpreted cautiously. Results Detection-based analysis General information Over the 10-year study period, a total of 14,185 patients with at least one positive culture during a single hospitalization were recorded. After excluding 219 cases with missing hospitalization duration and 137 cases with incomplete antimicrobial susceptibility data for Staphylococcus aureus, 13,829 hospitalization records were included in the final analysis. Among these, 1,550 unique Staphylococcus aureus isolates were identified (only the first isolate per hospitalization was included, and duplicates were excluded). The detection rate of S. aureus was calculated as follows: Detection rate of Staphylococcus aureus =1550/13829*100=11.21%.(95% CI: 10.7%~11.7%) A total of 433 MRSA isolates were identified among the 1,550 S. aureus isolates, yielding a detection rate of: Detection rate of MRSA=433/1550*100=27.94%.(95% CI: 25.71%~30.17%) Clinical and demographic characteristics Among all S. aureus isolates, 821 were from male patients and 729 from female patients, with a mean age of 55.89 years. The MRSA detection rates were 28.26%(232/821) in males and 27.57%(201/729) in females, showing no statistically significant difference by gender. There was also no significant difference in mean age between MRSA and MSSA cases. Detailed data are presented in Table 1. Table 1patient demographic dataCategoryMRSAMSSAχ²/t p GenderMale2325890.090.764Female201528Total4331117Age56.92 ± 13.5755.50 ± 13.671.84860.0647 Table 1patient demographic dataCategoryMRSAMSSAχ²/t p GenderMale2325890.090.764Female201528Total4331117Age56.92 ± 13.5755.50 ± 13.671.84860.0647 patient demographic data The 433 MRSA isolates were distributed across 23 departments. The highest number of MRSA isolates was detected in the Head and Neck Surgery Ward (54/185, 29.19%), while the highest detection rates were observed in the Neurosurgery Ward (18/36, 50%) and the Interventional Therapy Ward (2/4, 50%). The differences in MRSA detection rates among departments were statistically significant (χ²=55.1186, P < 0.001). Infection-specific analysis Of the 148 MRSA isolates classified as MRSA-associated hospital-acquired infection cases (34.18% of all 433 MRSA isolates), the predominant infection sites were the lower respiratory tract (60 cases, 40.54%) and surgical sites (32 cases, 21.62%); the remaining 56 cases (37.84%) involved other infection sites, including soft tissue infections (11 cases). The case enrollment methodology and overall results of Staphylococcus aureus are detailed in Fig. 1. Fig. 1Case enrollment methodology and overall results of Staphylococcus aureus Case enrollment methodology and overall results of Staphylococcus aureus There were 1,117 methicillin-sensitive Staphylococcus aureus (MSSA) isolates detected, among which 254 (22.74%) were classified as MSSA-associated hospital-acquired infections, mainly lower respiratory tract infections (75 cases), surgical site infections (61 cases), and bloodstream infections (37 cases). The proportion of detections classified as hospital-acquired infections was significantly higher among MRSA isolates than among MSSA isolates (χ² = 21.2621, P < 0.001). The Head and Neck Surgery Ward had the highest number of MRSA-associated hospital-acquired infections (31 cases), with surgical site infections being the most prevalent (18 out of 31 cases). See Table 2 for details. Table 2Distribution of MRSA by clinical departmentDepartmentNumber of MRSA detectionsMRSA Detection Rate (%)Number of Hospital-acquired Infection Cases by MRSASites of Hospital-acquired Infection by MRSALower Respiratory Tract InfectionSurgical Site InfectionOtherHead and Neck Surgery5429.193111182Head and Neck Radiotherapy4324.02187011Thoracic Surgery3642.86101000Orthopedic and Soft Tissue Surgery3330.844013Gynecologic Oncology3227.595023ICU2943.2813706Thoracic Radiotherapy2528.098611Comprehensive Medicine2223.45203Thoracic Medical Oncology2127.635212General Medicine2042.551001Head and Neck Lymphoma1829.518107Neurosurgery18506501Breast Surgery1615.389063Abdominal Radiotherapy1523.4410415Abdominal Medical Oncology12240000Radiation Oncology Comprehensive Ward1126.832101Gastric Surgery923.686114Integrated Traditional Chinese and Western Medicine522.733201Urology416.673111Hepatobiliary and Pancreatic Surgery4161001Colorectal Surgery3250000Interventional Therapy2500000Phase I Clinical Trial Ward150000Total43327.94148603256χ²55.1186 P < 0.001MRSA Detection Rate = (Number of MRSA isolates detected during a specified period / Total number of Staphylococcus aureus isolates detected during the same period) × 100% Table 2Distribution of MRSA by clinical departmentDepartmentNumber of MRSA detectionsMRSA Detection Rate (%)Number of Hospital-acquired Infection Cases by MRSASites of Hospital-acquired Infection by MRSALower Respiratory Tract InfectionSurgical Site InfectionOtherHead and Neck Surgery5429.193111182Head and Neck Radiotherapy4324.02187011Thoracic Surgery3642.86101000Orthopedic and Soft Tissue Surgery3330.844013Gynecologic Oncology3227.595023ICU2943.2813706Thoracic Radiotherapy2528.098611Comprehensive Medicine2223.45203Thoracic Medical Oncology2127.635212General Medicine2042.551001Head and Neck Lymphoma1829.518107Neurosurgery18506501Breast Surgery1615.389063Abdominal Radiotherapy1523.4410415Abdominal Medical Oncology12240000Radiation Oncology Comprehensive Ward1126.832101Gastric Surgery923.686114Integrated Traditional Chinese and Western Medicine522.733201Urology416.673111Hepatobiliary and Pancreatic Surgery4161001Colorectal Surgery3250000Interventional Therapy2500000Phase I Clinical Trial Ward150000Total43327.94148603256χ²55.1186 P < 0.001MRSA Detection Rate = (Number of MRSA isolates detected during a specified period / Total number of Staphylococcus aureus isolates detected during the same period) × 100% Distribution of MRSA by clinical department MRSA Detection Rate = (Number of MRSA isolates detected during a specified period / Total number of Staphylococcus aureus isolates detected during the same period) × 100% Changes in MRSA detection rates and antimicrobial susceptibility patterns Over the 10-year period, the overall detection rate of Staphylococcus aureus was 11.21%(1550/13829)(95% CI: 10.7%~11.7%), with fluctuations across different years, but the differences were not statistically significant (χ²=10.574, p = 0.306). The overall detection rate of MRSA was 27.94%(433/1550)(95% CI: 25.71%~30.17%), showing an initial increase followed by a decrease from 2015 to 2024. The detection rate peaked in 2018 at 35.48%, and subsequently declined with fluctuations. However, the annual differences in MRSA detection rates were also not statistically significant (χ²=11.044, p = 0.273). See Table 3; Fig. 2 for details. Table 3Comparison of MRSA detection rates in different yearsYearDetection of Staphylococcus aureusDetection of MRSAStaphylococcus aureus (S. aureus)Non-Staphylococcus aureusDetection Rate of S. aureus (%)MRSAMSSADetection Rate of MRSA (%)2015135119010.192910621.482016130102711.24339725.382017186137411.925313328.49201815514139.895510035.482019152112211.933911325.66202010692510.28317529.252021163140010.435211131.902022138101711.953210623.192023165117012.364811729.092024220164111.826115927.73Total155012,27911.21433111727.94χ²10.57411.044 P 0.3060.273MRSA: Methicillin-resistant Staphylococcus aureusMSSA: Methicillin-susceptible Staphylococcus aureusThe MRSA detection rate was calculated using S. aureus isolates as the denominator Table 3Comparison of MRSA detection rates in different yearsYearDetection of Staphylococcus aureusDetection of MRSAStaphylococcus aureus (S. aureus)Non-Staphylococcus aureusDetection Rate of S. aureus (%)MRSAMSSADetection Rate of MRSA (%)2015135119010.192910621.482016130102711.24339725.382017186137411.925313328.49201815514139.895510035.482019152112211.933911325.66202010692510.28317529.252021163140010.435211131.902022138101711.953210623.192023165117012.364811729.092024220164111.826115927.73Total155012,27911.21433111727.94χ²10.57411.044 P 0.3060.273MRSA: Methicillin-resistant Staphylococcus aureusMSSA: Methicillin-susceptible Staphylococcus aureusThe MRSA detection rate was calculated using S. aureus isolates as the denominator Comparison of MRSA detection rates in different years MRSA: Methicillin-resistant Staphylococcus aureus MSSA: Methicillin-susceptible Staphylococcus aureus The MRSA detection rate was calculated using S. aureus isolates as the denominator Fig. 2Detection rates of MRSA in different years. From 2015 to 2024, the detection rate of MRSA showed an initial rise followed by a decline; however, the year-to-year difference was not statistically significant Detection rates of MRSA in different years. From 2015 to 2024, the detection rate of MRSA showed an initial rise followed by a decline; however, the year-to-year difference was not statistically significant MRSA remained fully susceptible to daptomycin, linezolid, tigecycline, and vancomycin. For the remaining 12 antibiotics, MRSA resistance patterns fluctuated over time. Exploratory comparisons suggested interannual differences in resistance rates for erythromycin, chloramphenicol, and moxifloxacin. Because multiple antimicrobial agents were assessed and no formal correction for multiple comparisons was applied, these findings should be interpreted cautiously. See Table 4; Fig. 3 for details. Table 4Resistance rates of MRSA to antimicrobial agents by year YearDaptomycinLinezolidTigecyclineVancomycinErythromycinClindamycinCeftriaxoneTetracycline20150/28 (0)0/28 (0)NA0/28 (0)25/28(89.29)26/29(89.66)29/30(96.67)7/30(23.33)20160/33 (0)0/32 (0)NA0/32 (0)26/33(78.79)25/32(78.13)34/35(97.14)11/33(33.33)20170/53 (0)0/50 (0)NA0/52 (0)60/63(95.24)51/55(92.73)62/65(95.38)25/64(39.06)20180/56 (0)0/54 (0)0/37 (0)0/57 (0)41/55(74.55)37/56(66.07)19/20(95.00)20/58(34.48)20190/39 (0)0/40 (0)0/39 (0)0/40 (0)28/38(73.68)28/38(73.68)NA12/39(30.77)20200/29 (0)0/31 (0)0/29 (0)0/29 (0)19/27(70.37)20/28(71.43)NA13/31(41.94)20210/41 (0)0/56 (0)0/57 (0)0/55 (0)44/51(86.27)37/53(69.81)NA18/56(32.14)20220/24 (0)0/33 (0)0/32 (0)0/31 (0)26/33(78.79)25/33(75.76)NA8/32(25.00)20230/30 (0)0/48 (0)0/45 (0)0/44 (0)34/47(72.34)35/48(72.92)NA12/47(25.53)20240/49 (0)0/62 (0)0/59 (0)0/59 (0)47/61(77.05)47/61(77.05)NA15/60(25.00)Total0/382 (0)0/434 (0)0/298 (0)0/427 (0)350/436(80.28)331/433(76.44)144/150(96.00)141/450(31.33)MRSA Resistance Rates Over Yearsχ²17.72116.5050.6427.091 P 0.0390.0571.000*0.628YearGentamicinLevofloxacinCiprofloxacinMoxifloxacinChloramphenicolTrimethoprim-SulfamethoxazoleRifampicinQuinupristin/Dalfopristin20154/29(13.79)3/29(10.34)4/29(13.79)0/29(0)NA3/30(10.00)0/29(0)0/28(0)20163/34(8.82)4/33(12.12)4/36(11.11)0/32(0)NA1/35(2.86)0/32(0)0/31(0)20174/68(5.88)7/72(9.72)7/66(10.61)4/60(6.67)NA2/67(2.99)4/67(5.97)0/63(0)20183/60(5.00)9/62(14.52)9/56(16.07)8/55(14.55)4/34(11.76)2/62(3.23)2/61(3.28)2/55(3.64)20191/39(2.56)4/40(10.00)4/38(10.53)3/39(7.69)1/39(2.56)0/40(0)0/39(0)0/39(0)20201/33(3.03)4/32(12.5)4/33(12.12)4/30(13.33)1/27(3.70)2/31(6.45)0/31(0)1/28(3.57)20210/57(0.00)4/61(6.56)6/59(10.17)1/55(1.82)8/56(14.29)3/53(5.66)0/54(0)0/53(0)20221/33(3.03)7/34(20.59)7/33(21.21)7/32(21.88)2/33(6.06)2/31(6.45)1/31(3.23)0/32(0)20235/52(9.62)10/44(22.73)11/52(21.15)10/48(20.83)1/46(2.17)2/52(3.85)3/48(6.25)0/48(0)20247/61(11.48)6/59(10.17)7/62(11.29)5/62(8.06)2/61(3.28)1/63(1.59)5/61(8.2)1/61(1.64)Total29/466(6.22)58/466(12.45)63/464(13.58)42/442(9.50)19/296(6.42)18/464(3.88)15/453(3.31)4/438(0.91)MRSA Resistance Rates Over Yearsχ²13.1489.6336.38626.04213.5727.29010.4027.338 P 0.1560.3810.7010.0020.027*0.539*0.168*0.378*Note: Data cells are shown as no. resistant/no. tested (%)NA indicates that the antimicrobial agent was not tested or data were unavailable for that year. * indicates Fisher’s exact test Table 4Resistance rates of MRSA to antimicrobial agents by year YearDaptomycinLinezolidTigecyclineVancomycinErythromycinClindamycinCeftriaxoneTetracycline20150/28 (0)0/28 (0)NA0/28 (0)25/28(89.29)26/29(89.66)29/30(96.67)7/30(23.33)20160/33 (0)0/32 (0)NA0/32 (0)26/33(78.79)25/32(78.13)34/35(97.14)11/33(33.33)20170/53 (0)0/50 (0)NA0/52 (0)60/63(95.24)51/55(92.73)62/65(95.38)25/64(39.06)20180/56 (0)0/54 (0)0/37 (0)0/57 (0)41/55(74.55)37/56(66.07)19/20(95.00)20/58(34.48)20190/39 (0)0/40 (0)0/39 (0)0/40 (0)28/38(73.68)28/38(73.68)NA12/39(30.77)20200/29 (0)0/31 (0)0/29 (0)0/29 (0)19/27(70.37)20/28(71.43)NA13/31(41.94)20210/41 (0)0/56 (0)0/57 (0)0/55 (0)44/51(86.27)37/53(69.81)NA18/56(32.14)20220/24 (0)0/33 (0)0/32 (0)0/31 (0)26/33(78.79)25/33(75.76)NA8/32(25.00)20230/30 (0)0/48 (0)0/45 (0)0/44 (0)34/47(72.34)35/48(72.92)NA12/47(25.53)20240/49 (0)0/62 (0)0/59 (0)0/59 (0)47/61(77.05)47/61(77.05)NA15/60(25.00)Total0/382 (0)0/434 (0)0/298 (0)0/427 (0)350/436(80.28)331/433(76.44)144/150(96.00)141/450(31.33)MRSA Resistance Rates Over Yearsχ²17.72116.5050.6427.091 P 0.0390.0571.000*0.628YearGentamicinLevofloxacinCiprofloxacinMoxifloxacinChloramphenicolTrimethoprim-SulfamethoxazoleRifampicinQuinupristin/Dalfopristin20154/29(13.79)3/29(10.34)4/29(13.79)0/29(0)NA3/30(10.00)0/29(0)0/28(0)20163/34(8.82)4/33(12.12)4/36(11.11)0/32(0)NA1/35(2.86)0/32(0)0/31(0)20174/68(5.88)7/72(9.72)7/66(10.61)4/60(6.67)NA2/67(2.99)4/67(5.97)0/63(0)20183/60(5.00)9/62(14.52)9/56(16.07)8/55(14.55)4/34(11.76)2/62(3.23)2/61(3.28)2/55(3.64)20191/39(2.56)4/40(10.00)4/38(10.53)3/39(7.69)1/39(2.56)0/40(0)0/39(0)0/39(0)20201/33(3.03)4/32(12.5)4/33(12.12)4/30(13.33)1/27(3.70)2/31(6.45)0/31(0)1/28(3.57)20210/57(0.00)4/61(6.56)6/59(10.17)1/55(1.82)8/56(14.29)3/53(5.66)0/54(0)0/53(0)20221/33(3.03)7/34(20.59)7/33(21.21)7/32(21.88)2/33(6.06)2/31(6.45)1/31(3.23)0/32(0)20235/52(9.62)10/44(22.73)11/52(21.15)10/48(20.83)1/46(2.17)2/52(3.85)3/48(6.25)0/48(0)20247/61(11.48)6/59(10.17)7/62(11.29)5/62(8.06)2/61(3.28)1/63(1.59)5/61(8.2)1/61(1.64)Total29/466(6.22)58/466(12.45)63/464(13.58)42/442(9.50)19/296(6.42)18/464(3.88)15/453(3.31)4/438(0.91)MRSA Resistance Rates Over Yearsχ²13.1489.6336.38626.04213.5727.29010.4027.338 P 0.1560.3810.7010.0020.027*0.539*0.168*0.378*Note: Data cells are shown as no. resistant/no. tested (%)NA indicates that the antimicrobial agent was not tested or data were unavailable for that year. * indicates Fisher’s exact test Resistance rates of MRSA to antimicrobial agents by year Note: Data cells are shown as no. resistant/no. tested (%) NA indicates that the antimicrobial agent was not tested or data were unavailable for that year. * indicates Fisher’s exact test Fig. 3Trend of MRSA resistance spectrum. The resistance rates of MRSA to erythromycin, clindamycin, moxifloxacin, and chloramphenicol fluctuated markedly across years; however, there is insufficient evidence to suggest a stable, statistically significant annual increasing or decreasing trend in resistance rates Trend of MRSA resistance spectrum. The resistance rates of MRSA to erythromycin, clindamycin, moxifloxacin, and chloramphenicol fluctuated markedly across years; however, there is insufficient evidence to suggest a stable, statistically significant annual increasing or decreasing trend in resistance rates The Cochran-Armitage trend test is designed to detect monotonic trends in proportions across ordered categories. By incorporating the ordinal nature of the time variable, it can detect directional changes in resistance rates. The Cochran-Armitage trend test results for these three antibiotics were as follows: erythromycin (Z = -1.96, P = 0.0496), chloramphenicol (Z = -1.34, P = 0.180), and moxifloxacin (Z = 0.53, P = 0.595). No distinct upward or downward trends were observed for chloramphenicol or moxifloxacin. For erythromycin, the result suggested a possible decreasing trend; however, the P-value was very close to 0.05 and the analysis was exploratory, so the strength of evidence was weak and the result should be interpreted with caution. Further analysis was performed using weighted linear regression (percentage point change per year), with the total number of strains per year as weight, to fit a linear model of resistance rate (%) against year (as a continuous variable). The results showed that for erythromycin: slope (annual change) = -1.31% points per year (i.e., the MRSA resistance rate decreased by an average of 1.31% per year), with 95% confidence interval = (-2.84%, + 0.23%); for chloramphenicol: slope (annual change) = -0.20% points per year (i.e., the resistance rate decreased by an average of 0.20% per year), 95% CI = (-1.58%, + 1.18%); for moxifloxacin: slope (annual change) = + 0.61% points per year (i.e., the resistance rate increased by an average of 0.61% per year), 95% CI = (-1.94%, + 3.16%). Because the 95% confidence interval of the slope includes 0, no statistically significant temporal trend was identified. The Cochran-Armitage trend test and weighted linear regression evaluate different aspects of the data. The Cochran-Armitage test assesses whether a monotonic trend may be present, whereas weighted linear regression estimates the magnitude and uncertainty of a linear annual change. Therefore, the borderline Cochran-Armitage result for erythromycin may suggest a possible monotonic decrease, while the regression analysis indicates that the magnitude of the annual decrease was statistically imprecise because the 95% confidence interval included 0. Overall, there is insufficient evidence to conclude that erythromycin resistance had a stable, statistically robust decreasing trend over time. Notably, MRSA showed lower resistance rates to gentamicin (MRSA:6.22%, MSSA:10.73%, p = 0.005) and trimethoprim-sulfamethoxazole (MRSA:3.88%, MSSA:5.86%,p = 0.106) compared to MSSA, with a statistically significant difference in resistance rates to gentamicin between MRSA and MSSA. Discussion This study retrospectively investigated the distribution and antimicrobial resistance trends of MRSA in a single cancer specialty hospital between 2015 and 2024. The overall MRSA detection rate among Staphylococcus aureus isolates was 27.94%. Because this study was based primarily on clinical specimen detection and surveillance classification, the findings should be interpreted as reflecting MRSA detection, colonization, and MRSA-associated hospital-acquired infections rather than the overall incidence of clinical MRSA infection among all hospitalized patients. In this study, the MRSA detection rate peaked in 2018 (35.48%) and subsequently declined, although interannual variations were not statistically significant (p > 0.05). In contrast, similar studies conducted in other regions have commonly reported an increasing trend in MRSA detection rates [11, 12]. Although the current study did not identify a similar increasing pattern, it is noteworthy that MRSA detection rates in comparable studies frequently exceed 30%. These findings suggest that MRSA epidemiological trends exhibit geographical variation, yet overall detection rates remain consistently high, underscoring that MRSA continues to represent a major global public health challenge. This study showed that among all hospitalized patients with Staphylococcus aureus detection, 25.94% (402/1,550 isolates) were classified as hospital-acquired infections, while the remaining 1,148 were classified as community-acquired infections or colonization. Among the 433 MRSA detections, 148 were classified as MRSA-associated hospital-acquired infections. These findings indicate that MRSA surveillance in cancer specialty hospitals is relevant to infection prevention, but detection data alone should not be interpreted as direct evidence of clinical infection or disease burden. From a departmental distribution perspective, four of the top five departments with the highest number of MRSA detections were surgical wards. The Head and Neck Surgery Ward had the highest number of MRSA isolates and the highest number of MRSA-associated hospital-acquired infections, where surgical site infections (SSIs) accounted for 58% (18 out of 31) of cases. Previous studies have indicated that MRSA-associated SSIs represent serious postoperative complications, and patients with head and neck cancer may be at increased risk due to the characteristics of their disease [13]. This elevated risk may be related to factors such as comorbidities, cancer diagnosis, concurrent neck dissection, tracheostomy, and nasal colonization [14, 15]. The department with the highest MRSA detection rate was the Neurosurgery Ward. Among MRSA-associated hospital-acquired infections in this ward, lower respiratory tract infection was the main infection site. This pattern may be related to factors such as surgical trauma, postoperative ICU admission, and prolonged hospital stays [16]. The ICU also showed a high number and detection rate of MRSA (29 isolates, 43.28%), among which 13 isolates were classified as MRSA-associated hospital-acquired infections, primarily involving the lower respiratory tract. Studies [17] have shown that ICU patients are at increased risk for hospital-acquired infections, including MRSA-associated infections, which may be associated with severe clinical outcomes and increased healthcare costs. These findings support continued MRSA surveillance and infection prevention efforts in ICU settings. In addition, the Head and Neck Radiation Oncology Ward and Thoracic Surgery Ward had relatively high numbers of MRSA detections and MRSA-associated hospital-acquired infections. This distribution pattern suggests that MRSA was widely detected across the hospital while showing concentration in specific departments and infection sites. Departments with higher MRSA detection or MRSA-associated hospital-acquired infection burden, such as Head and Neck Surgery, Neurosurgery, and ICU, may benefit from strengthened surveillance, department-specific infection prevention measures, and antimicrobial stewardship. Potential strategies include MRSA screening when clinically appropriate, decolonization protocols for selected patients, perioperative infection control, patient isolation procedures, environmental cleaning and disinfection, and judicious antimicrobial stewardship. In this study, MRSA remained fully susceptible to daptomycin, linezolid, tigecycline, and vancomycin, with resistance rates of 0%. Among other antimicrobial agents, MRSA showed relatively low resistance rates to quinupristin/dalfopristin (0.91%), rifampicin (3.31%), trimethoprim-sulfamethoxazole (3.88%), gentamicin (6.22%), chloramphenicol (6.42%), moxifloxacin (9.50%), levofloxacin (12.45%), and ciprofloxacin (13.58%), which is consistent with findings from other studies [6]. However, because detailed clinical stratification data were unavailable, these overall resistance profiles should be interpreted as local surveillance baselines rather than as direct guidance for individualized empirical therapy across all cancer subgroups. Over the past decade, the annual differences in resistance rates of MRSA to the remaining 13 antimicrobial agents—except for erythromycin, chloramphenicol, and moxifloxacin—were not statistically significant. Nevertheless, in the absence of molecular epidemiological data, it is impossible to determine whether there are dynamic shifts among different MRSA-resistant clones (i.e., one clone declining as another emerges). The situation may differ in other regions, where studies have shown an increasing trend in MRSA resistance to certain antimicrobial agents [7]. A comparison of antimicrobial resistance patterns between MRSA and MSSA revealed that MRSA demonstrated significantly higher resistance rates to most antimicrobial agents, with statistically significant differences observed for the majority of drugs. These findings are consistent with those reported in other studies [6]. Notably, MRSA exhibited lower resistance rates to gentamicin and trimethoprim-sulfamethoxazole compared to MSSA, with a statistically significant difference observed for gentamicin. Some studies have also indicated higher resistance rates in MSSA than in MRSA to certain antibiotics [18]. A study conducted in the United States [19] found that the incidence of MSSA-associated hospital-acquired infections (31.3 per 100,000) was 1.8 times higher than that of MRSA (17.5 per 100,000), underscoring that MSSA remains a substantial public health concern that requires continued attention. These findings support the value of continuous antimicrobial resistance surveillance and locally tailored infection prevention measures for MRSA and MSSA. Conclusion This study retrospectively investigated the distribution and antimicrobial resistance trends of methicillin-resistant Staphylococcus aureus (MRSA) in a single cancer specialty hospital from 2015 to 2024. MRSA detection and MRSA-associated hospital-acquired infections showed departmental heterogeneity. Head and Neck Surgery accounted for the largest number of MRSA-associated hospital-acquired infections, whereas the Neurosurgery Ward had the highest MRSA detection rate. Surgical site infections and lower respiratory tract infections were the main infection sites among MRSA-associated hospital-acquired infections. During the 10-year study period, the overall resistance rate of MRSA to erythromycin remained high, with only weak evidence of a possible decreasing trend; this finding should be interpreted cautiously because the result was borderline and the analyses were exploratory. Resistance rates to most other tested antimicrobial agents did not show clear increasing or decreasing trends. Overall, these surveillance data may inform local empirical therapy, antimicrobial stewardship, and department-specific infection prevention strategies. However, because molecular epidemiological characterization, antimicrobial consumption data, and detailed clinical stratification were unavailable, the findings should not be used as direct evidence for individualized treatment decisions. Further studies incorporating high-risk subgroup characteristics, antimicrobial exposure, and clonal evolution mechanisms are needed. Limitations This study has several limitations that somewhat restrict the in-depth mechanistic exploration and clinical translational significance of our findings. First, the lack of molecular epidemiological data significantly limits our ability to elucidate the mechanisms underlying the evolution of resistance trends. For instance, the driving factors behind the observed fluctuations in erythromycin resistance and the slight upward trend in moxifloxacin resistance may be heterogeneous. These changes could stem from the nosocomial spread and expansion of specific highly-resistant clones (e.g., ST72), or they could result from the horizontal acquisition of new resistance elements by existing strains under antimicrobial selective pressure. Without molecular typing data, we are unable to verify clonal shifts or explore the genetic characteristics of the strains, thereby precluding us from determining whether the resistance trends are driven by clonal replacement or the horizontal transfer of resistance genes. Second, the lack of detailed clinical stratification data limits the applicability of our findings to individualized clinical decision-making. Cancer patients represent a highly heterogeneous population; the risk of MRSA infection and resistance profiles can vary substantially between patients with solid tumors versus hematological malignancies, those undergoing surgery versus high-intensity chemotherapy or hematopoietic stem cell transplantation, and those with or without severe immunosuppression. Due to surveillance system constraints, this study was unable to collect data on cancer types, disease severity, treatment phases, and immunosuppression status. Consequently, the MRSA detection and resistance rates reported herein reflect the average levels across the entire hospitalized cancer population in this specialty hospital and do not reveal differences among distinct clinical subgroups. This means we cannot determine whether the observed resistance distribution was driven by specific high-risk subgroups, such as patients with hematological malignancies complicated by neutropenia, or was broadly distributed across cancer patients. This limitation reduces the utility of these data for individualized empirical therapy. Furthermore, the absence of antimicrobial consumption data precludes us from establishing a direct correlation between shifts in resistance patterns and antimicrobial selective pressure, further limiting a comprehensive understanding of the drivers of resistance. Given these limitations, the findings of this study should be interpreted with caution. Although our surveillance data reflect the overall epidemiological and resistance baselines of MRSA in this single-center cancer specialty hospital, the absence of molecular transmission data, antimicrobial consumption data, and detailed susceptible-population profiles limits causal interpretation. Therefore, it would be unwarranted to attribute the observed resistance patterns to a single factor or to directly extrapolate these average-level data to all cancer subgroups. In future studies, we aim to integrate molecular typing, granular clinical characteristics, and antimicrobial consumption data to better understand the evolution of MRSA in cancer populations and to improve targeted prevention and antimicrobial stewardship strategies.